Literature DB >> 9593121

In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials.

F Soriano1, R Fernández-Roblas, R Calvo, G García-Calvo.   

Abstract

The comparative in vitro activity of the ketolide HMR 3647 (RU 66647) and those of structurally related macrolide-lincosamide-streptogramin compounds (erythromycin, roxithromycin, azithromycin, clarithromycin, josamycin, lincomycin, pristinamycin, and quinupristin-dalfopristin) as well as those of benzylpenicillin, doxycycline, vancomycin, teicoplanin, levofloxacin, and rifapentine against 247 aerobic and facultative non-spore-forming gram-positive bacilli were determined by an agar dilution method. The ketolide was active against most organisms tested except Corynebacterium striatum, coryneform CDC group 12, and Oerskovia spp. The frequency of resistance to erythromycin and other macrolides as well as that to lincomycin was high. Pristinamycin and, to a lesser extent, quinupristin-dalfopristin were very active, but resistance to these agents was present in some strains of Rhodococcus equi, Listeria spp., C. striatum, Erysipelothrix rhusiopathiae, and Oerskovia spp. HMR 3647 was very active against all erythromycin-sensitive and many erythromycin-nonsusceptible strains, especially Corynebacterium minutissimum, Corynebacterium pseudodiphtheriticum, Corynebacterium amycolatum, and Corynebacterium jeikeium. In vitro resistance to benzylpenicillin was common, but doxycycline, vancomycin, and teicoplanin were very active against most organisms tested except E. rhusiopathiae, against which glycopeptide antibiotics were not active. The in vitro activity of levofloxacin was remarkable, but resistance to this agent was common for C. amycolatum, Corynebacterium urealyticum, C. jeikeium, and Oerskovia spp. strains. Rifapentine was also very active in vitro against many organisms, but resistance to this agent was always present in E. rhusiopathiae and was very common in C. striatum and C. urealyticum.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593121      PMCID: PMC105739          DOI: 10.1128/AAC.42.5.1028

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Statement 1996 CA-SFM Zone sizes and MIC breakpoints for non-fastidious organisms.

Authors: 
Journal:  Clin Microbiol Infect       Date:  1996-02       Impact factor: 8.067

2.  In vitro susceptibility of Corynebacterium group D2 and Corynebacterium jeikeium to twelve antibiotics.

Authors:  A Philippon; F Bimet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

Review 3.  Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria.

Authors:  R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

4.  Species identities and antimicrobial susceptibilities of corynebacteria isolated from various clinical sources.

Authors:  P Riegel; R Ruimy; R Christen; H Monteil
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

5.  In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.

Authors:  T Schülin; C B Wennersten; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.

Authors:  L M Ednie; S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 7.  Clinical microbiology of coryneform bacteria.

Authors:  G Funke; A von Graevenitz; J E Clarridge; K A Bernard
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

8.  In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.

Authors:  C Jamjian; D J Biedenbach; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

9.  Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents.

Authors:  F Soriano; J Zapardiel; E Nieto
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

10.  Comparative in vitro activities of new quinolones against coryneform bacteria.

Authors:  L Martínez-Martínez; A I Suárez; M C Ortega; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more
  16 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  In vitro activity of quinupristin and dalfopristin in combination and alone against coryneform bacteria.

Authors:  G Funke; R Troxler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

Review 3.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis.

Authors:  J M Rolain; M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Clearance of Cellulosimicrobium cellulans bacteremia in a child without central venous catheter removal.

Authors:  Marie-Claire Rowlinson; David A Bruckner; Claudia Hinnebusch; Karin Nielsen; Jaime G Deville
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

6.  Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.

Authors:  K L Credito; L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

7.  Controlled trial of a 5-day course of telithromycin versus doxycycline for treatment of mild to moderate scrub typhus.

Authors:  Dong-Min Kim; Ki Dong Yu; Ji Hyun Lee; Hyun Kuk Kim; Seung-Hyun Lee
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

8.  The isolation of Corynebacterium coyleae from clinical samples: clinical and microbiological data.

Authors:  M I Fernández-Natal; J A Sáez-Nieto; R Fernández-Roblas; M Asencio; S Valdezate; S Lapeña; R H Rodríguez-Pollán; J M Guerra; J Blanco; F Cachón; F Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-09       Impact factor: 3.267

Review 9.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Isolation of Corynebacterium ureicelerivorans from normally sterile sites in humans.

Authors:  M I Fernández-Natal; J A Sáez-Nieto; S Valdezate; R H Rodríguez-Pollán; S Lapeña; F Cachón; F Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-12-17       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.